Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VNDA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVanda Pharmaceuticals expands board to seven, appoints Charles C. Duncan as director
Filed April 22, 2026 · Period ending April 22, 2026 · ~1 min read
Key Changes
-
medium
Board expanded from six to seven members and appointed Charles C. Duncan, Ph.D., as independent Class II director with term expiring at 2026 annual meeting. Duncan meets SEC and Nasdaq independence standards.
Item 5.02 verify on EDGAR → -
low
Duncan receives $390,000 initial restricted stock unit grant vesting in four equal annual installments starting April 2027, plus $50,000 annual cash fee paid quarterly. All RSUs accelerate upon change of control.
Item 5.02 verify on EDGAR → -
low
Duncan eligible for annual RSU grants valued at $260,000 after each stockholder meeting starting 2026, vesting after one year or immediately upon change of control.
Item 5.02 verify on EDGAR → -
medium
Company attached press release dated April 22, 2026 as exhibit; content not disclosed in filing body.
Item 9.01 verify on EDGAR →
Summary
Vanda Pharmaceuticals expanded its board from six to seven directors and immediately filled the new seat with Charles C. Duncan, Ph.D., who qualifies as independent under exchange rules. Duncan's appointment as a Class II director runs through the 2026 annual meeting.
The company granted him a standard compensation package: $390,000 in restricted stock units vesting over four years, $50,000 annual cash retainer, and eligibility for $260,000 annual equity grants. All equity awards accelerate if the company is acquired. For retail investors, board expansion typically signals either preparation for growth initiatives or response to governance pressure.
The timing—mid-year rather than at an annual meeting—and the attached press release suggest this may be part of a broader announcement. Duncan's background and committee assignments, once disclosed, will indicate whether Vanda is strengthening specific capabilities like clinical development, finance, or commercial operations. Watch for the press release content and any subsequent Form 4 filings showing Duncan's actual share grants. If Vanda announces strategic initiatives or partnerships in coming weeks, the board expansion may be preparatory. The change-of-control provisions in all equity awards are standard but worth noting if acquisition rumors emerge.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 22, 2026, the Board of Directors (the “Board”) of Vanda Pharmaceuticals Inc. (the “Company”) expanded the size of the Board from six to seven members, effective immediately and appointed Charles C. Duncan, Ph.D., as a director of the Company to fill the vacancy created by the expansion. Dr. Duncan will serve as a Class II director with an initial term that will expire at the Company’s 2026 annual meeting of stockholders.
The Board added a seventh seat and appointed Dr. Charles C. Duncan to fill it as a Class II director. His initial term runs until the 2026 annual stockholder meeting. The Board determined Dr. Duncan qualifies as an independent director under SEC and Nasdaq rules.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Pursuant to the Company’s outside director compensation program, Dr. Duncan was granted an initial restricted stock unit award with a fixed grant date value equal to $390,000 as of April 22, 2026, with the number of shares of common stock underlying the award to be determined based on such value calculated in accordance with ASC 718. The restricted stock units will vest in four equal installments while Dr. Duncan continues to provide service as a member of the Board, with the first annual vest taking place on April 22, 2027. In the event of a change of control of the Company, the restricted stock units will become fully vested.
Dr. Duncan received an initial restricted stock unit award valued at $390,000 that vests in four equal annual installments starting April 22, 2027. The RSUs fully accelerate upon a change of control. The actual share count will be determined using ASC 718 accounting standards.
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Press release of Vanda Pharmaceuticals Inc. dated April 22, 2026.
The 8-K references an attached press release dated April 22, 2026 (Exhibit 99.1). The filing body itself does not disclose the content or subject matter of the press release, so the materiality and investor impact depend entirely on that exhibit, which is not provided in this filing text.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify